Relay Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Relay Therapeutics, Inc. (RLAY) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-02-26
- Relay Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- Relay Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- Relay Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Relay Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |